FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994699169> ?p ?o ?g. }

• W1994699169 endingPage "06" @default.
• W1994699169 startingPage "OT3" @default.
• W1994699169 abstract "Abstract Background: Epigenetic alterations in the genome, including abnormal DNA methylation and histone hypoacetylation, initiate and promote cancerous changes via several mechanisms, including inactivation of tumor suppressor genes. Preclinical investigations in breast cancer suggest that use of epigenetic modifiers results in re-expression of aberrantly silenced genes and proteins that represent important therapeutic targets (e.g. estrogen receptor alpha, ER). Combination therapy with a DNA methyltransferase inhibitor (DNMTI) and a histone deacetylase inhibitor (HDACI) has yielded superior ER reexpression and greater restoration of tamoxifen responsiveness than with HDACI alone. We hypothesize that clinically tolerable doses of the DNMTI 5-azacitidine (5-AZA) and the HDACI entinostat may not only effect changes in DNA methylation and gene expression, but also yield objective disease responses in women with advanced breast cancer. Trial design: This multicenter phase II study (NCT01349959) is enrolling patients with advanced human epidermal growth factor receptor 2 (HER2)-negative breast cancer with triple negative (ER/progesterone receptor [PR]/HER2−negative, Cohort A) or hormone-resistant (Cohort B) disease. Patients will receive 5-AZA 40 mg/m2 subcutaneously days 1–5 and 8–10 and entinostat 7 mg orally days 3 and 10 every 28 days. Because of the potential for re-expression of the ER with epigenetic agents, patients will be offered continuation of 5-AZA and entinostat at progression with the addition of hormonal therapy (investigator discretion). Mandatory tumor biopsies will be performed at baseline and after 8 weeks of therapy to evaluate correlative biomarkers. Eligibility Criteria: Eligible patients must be ≥ 18 years, have measurable locally advanced/metastatic triple-negative (at least one prior chemotherapy received adjuvant/metastatic setting) or hormone-resistant (must have received two prior hormonal agents and one prior chemotherapy) disease, adequate organ function and ECOG PS ≤ 2. Specific Aims: 1. Objective response rate (ORR) by RECIST 1.1 criteria. 2. Safety and tolerability 3. Progression-free survival, overall survival and clinical benefit rate. 4. Safety and toxicity data, feasibility and response rate where hormonal therapy is added to the combination under investigation at the time of progressive disease. 5. Pharmacokinetics, cytidine deaminase, changes from baseline of candidate gene methylation and expression in circulating deoxyribonucleic acid (DNA) and malignant tissue. Statistical Methods: Using a two-stage three-outcome design to assess the efficacy of the combination, a maximum of 30 patients (requiring 27 evaluable) will be accrued to each cohort unless undue toxicity is encountered for a maximum sample size of 60 patients. The study design tests the null hypothesis that the ORR is at most 5% against the alternative hypothesis that it is at least 20% with a type I error of 4% and power of 90%. Present and Targeted Accrual: This study has just opened to patient enrollment. We anticipate a rapid accrual of 60 patients within 1 year.br](Funding from Stand Up to Cancer and CTEP). Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT3-01-06." @default.
• W1994699169 created "2016-06-24" @default.
• W1994699169 creator A5003104262 @default.
• W1994699169 creator A5013334831 @default.
• W1994699169 creator A5014445762 @default.
• W1994699169 creator A5025523633 @default.
• W1994699169 creator A5056530735 @default.
• W1994699169 creator A5065233409 @default.
• W1994699169 creator A5071886988 @default.
• W1994699169 creator A5074741498 @default.
• W1994699169 creator A5078599450 @default.
• W1994699169 creator A5085782600 @default.
• W1994699169 creator A5088317474 @default.
• W1994699169 creator A5089577772 @default.
• W1994699169 creator A5090054973 @default.
• W1994699169 date "2011-12-01" @default.
• W1994699169 modified "2023-10-01" @default.
• W1994699169 title "OT3-01-06: A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer." @default.
• W1994699169 doi "https://doi.org/10.1158/0008-5472.sabcs11-ot3-01-06" @default.
• W1994699169 hasPublicationYear "2011" @default.
• W1994699169 type Work @default.
• W1994699169 sameAs 1994699169 @default.
• W1994699169 citedByCount "6" @default.
• W1994699169 countsByYear W19946991692012 @default.
• W1994699169 countsByYear W19946991692014 @default.
• W1994699169 countsByYear W19946991692015 @default.
• W1994699169 countsByYear W19946991692018 @default.
• W1994699169 countsByYear W19946991692022 @default.
• W1994699169 crossrefType "journal-article" @default.
• W1994699169 hasAuthorship W1994699169A5003104262 @default.
• W1994699169 hasAuthorship W1994699169A5013334831 @default.
• W1994699169 hasAuthorship W1994699169A5014445762 @default.
• W1994699169 hasAuthorship W1994699169A5025523633 @default.
• W1994699169 hasAuthorship W1994699169A5056530735 @default.
• W1994699169 hasAuthorship W1994699169A5065233409 @default.
• W1994699169 hasAuthorship W1994699169A5071886988 @default.
• W1994699169 hasAuthorship W1994699169A5074741498 @default.
• W1994699169 hasAuthorship W1994699169A5078599450 @default.
• W1994699169 hasAuthorship W1994699169A5085782600 @default.
• W1994699169 hasAuthorship W1994699169A5088317474 @default.
• W1994699169 hasAuthorship W1994699169A5089577772 @default.
• W1994699169 hasAuthorship W1994699169A5090054973 @default.
• W1994699169 hasConcept C104317684 @default.
• W1994699169 hasConcept C121608353 @default.
• W1994699169 hasConcept C126322002 @default.
• W1994699169 hasConcept C143998085 @default.
• W1994699169 hasConcept C150194340 @default.
• W1994699169 hasConcept C190727270 @default.
• W1994699169 hasConcept C2776202225 @default.
• W1994699169 hasConcept C2776239401 @default.
• W1994699169 hasConcept C2777176818 @default.
• W1994699169 hasConcept C2778305200 @default.
• W1994699169 hasConcept C2778311097 @default.
• W1994699169 hasConcept C2780110267 @default.
• W1994699169 hasConcept C2780737395 @default.
• W1994699169 hasConcept C41091548 @default.
• W1994699169 hasConcept C502942594 @default.
• W1994699169 hasConcept C530470458 @default.
• W1994699169 hasConcept C55493867 @default.
• W1994699169 hasConcept C64927066 @default.
• W1994699169 hasConcept C71924100 @default.
• W1994699169 hasConcept C84606932 @default.
• W1994699169 hasConcept C86803240 @default.
• W1994699169 hasConceptScore W1994699169C104317684 @default.
• W1994699169 hasConceptScore W1994699169C121608353 @default.
• W1994699169 hasConceptScore W1994699169C126322002 @default.
• W1994699169 hasConceptScore W1994699169C143998085 @default.
• W1994699169 hasConceptScore W1994699169C150194340 @default.
• W1994699169 hasConceptScore W1994699169C190727270 @default.
• W1994699169 hasConceptScore W1994699169C2776202225 @default.
• W1994699169 hasConceptScore W1994699169C2776239401 @default.
• W1994699169 hasConceptScore W1994699169C2777176818 @default.
• W1994699169 hasConceptScore W1994699169C2778305200 @default.
• W1994699169 hasConceptScore W1994699169C2778311097 @default.
• W1994699169 hasConceptScore W1994699169C2780110267 @default.
• W1994699169 hasConceptScore W1994699169C2780737395 @default.
• W1994699169 hasConceptScore W1994699169C41091548 @default.
• W1994699169 hasConceptScore W1994699169C502942594 @default.
• W1994699169 hasConceptScore W1994699169C530470458 @default.
• W1994699169 hasConceptScore W1994699169C55493867 @default.
• W1994699169 hasConceptScore W1994699169C64927066 @default.
• W1994699169 hasConceptScore W1994699169C71924100 @default.
• W1994699169 hasConceptScore W1994699169C84606932 @default.
• W1994699169 hasConceptScore W1994699169C86803240 @default.
• W1994699169 hasIssue "24_Supplement" @default.
• W1994699169 hasLocation W19946991691 @default.
• W1994699169 hasOpenAccess W1994699169 @default.
• W1994699169 hasPrimaryLocation W19946991691 @default.
• W1994699169 hasRelatedWork W2081036615 @default.
• W1994699169 hasRelatedWork W2103643613 @default.
• W1994699169 hasRelatedWork W2172254302 @default.
• W1994699169 hasRelatedWork W2247891169 @default.
• W1994699169 hasRelatedWork W2329953917 @default.
• W1994699169 hasRelatedWork W2604779289 @default.
• W1994699169 hasRelatedWork W2944780474 @default.
• W1994699169 hasRelatedWork W2953241133 @default.
• W1994699169 hasRelatedWork W4361257795 @default.
• W1994699169 hasRelatedWork W4361804906 @default.

• next